Comparison
Why is Lixte Biotechnology Holdings, Inc. ?
Unrated Stock - No Analysis Available
Quality key factors
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-10.10%
EBIT to Interest (avg)
-3.54
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.19
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
15.26%
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.08
EV to EBIT
-0.66
EV to EBITDA
-0.66
EV to Capital Employed
-2.18
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-286.78%
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Movement
8What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -2.62 MM
NET PROFIT(HY)
Higher at USD -1.49 MM
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -136.19 %
-3What is not working for the Company
ROCE(HY)
Lowest at -213.21%
CASH AND EQV(HY)
Lowest at USD 2.27 MM
Here's what is working for Lixte Biotechnology Holdings, Inc.
Operating Cash Flow
Highest at USD -2.62 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Profit
Higher at USD -1.49 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Debt-Equity Ratio
Lowest at -136.19 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Lixte Biotechnology Holdings, Inc.
Cash and Eqv
Lowest at USD 2.27 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents






